Jaka jest cena za Vertex Pharmaceuticals Incorporated (VRTX)

Cena za Vertex Pharmaceuticals Incorporated (VRTX) wynosi $519.38

Jaka jest kapitalizacja rynkowa dla Vertex Pharmaceuticals Incorporated (VRTX)

Kapitalizacja rynkowa dla Vertex Pharmaceuticals Incorporated (VRTX) wynosi $131.82B

Vertex Pharmaceuticals Incorporated (VRTX) Wskaźnik C/P

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Rok	Wskaźnik P/S	Zmień
2026 (TTM)	10.95	16.34%
2024	9.41	-11.43%
2023	10.62	28.30%
2022	8.28	10.84%
2021	7.47	-24.50%
2020	9.90	-26.71%
2019	13.50	-2.34%
2018	13.83	-7.73%
2017	14.99	42.14%
2016	10.54	-64.09%
2015	29.36	-38.95%
2014	48.08	248.85%
2013	13.78	137.01%
2012	5.82	20.56%
2011	4.82	-90.15%
2010	48.96	-32.70%
2009	72.75	199.01%
2008	24.33	61.60%
2007	15.06	-23.11%
2006	19.58	27.59%
2005	15.35	89.82%
2004	8.09	-29.86%
2003	11.53	54.66%
2002	7.45	-31.82%
2001	10.93	-82.35%
2000	61.94	0.00%

Rok

Wskaźnik P/S

Zmień

2026 (TTM)

10.95

16.34%

2024

9.41

-11.43%

2023

10.62

28.30%

2022

8.28

10.84%

2021

7.47

-24.50%

2020

9.90

-26.71%

2019

13.50

-2.34%

2018

13.83

-7.73%

2017

14.99

42.14%

2016

10.54

-64.09%

2015

29.36

-38.95%

2014

48.08

248.85%

2013

13.78

137.01%

2012

5.82

20.56%

2011

4.82

-90.15%

2010

48.96

-32.70%

2009

72.75

199.01%

2008

24.33

61.60%

2007

15.06

-23.11%

2006

19.58

27.59%

2005

15.35

89.82%

2004

8.09

-29.86%

2003

11.53

54.66%

2002

7.45

-31.82%

2001

10.93

-82.35%

2000

61.94

0.00%

Firma	Wskaźnik P/S	Różnica wskaźnika P/S	Kraj
Argenx SE ARGX.US	12.19	11.36%	NL
CSL Limited CSL.AX	3.75	-65.72%	AU
Moderna, Inc. MRNA.US	24.99	128.30%	US
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	4.81	-56.07%	BE

Firma

Wskaźnik P/S

Różnica wskaźnika P/S

Kraj